LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Начало・Списък с акции・United Therapeutics Corp

United Therapeutics Corp

Отворен

Сектор Здравеопазване

348.54 -1.04

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

347.69

Максимум

354.46

Ключови измерители
By Trading Economics
Приходи	-29M 278M
Продажби	37M 715M
P/E Средно за сектора	15.08 103.001
EPS	5.85
Марж на печалбата	38.901
Служители	1,168
EBITDA	-41M 386M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+5.25 upside

Дивиденти
By Dow Jones
Следващи печалби	30.10.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	702M 17B
Предишно отваряне	349.58
Предишно затваряне	348.54

Настроения в новините

By Acuity

50%

119 / 365 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

351.61 / 365.98 Подкрепа & съпротива

United Therapeutics Corp Графика

Свързани новини

4.09.2024 г., 23:21 ч. UTC

Печалби

Capricorn Metals: Expects FY25 to be 'Another Strong Year' for KGP Operations

4.09.2024 г., 23:20 ч. UTC

Топ новини

Johnson & Johnson Wins Over Longtime Holdout for Talc Settlement -- Update

4.09.2024 г., 23:20 ч. UTC

Печалби

Capricorn Metals FY24 Ebitda Margin 47% Vs 50% Year Prior

4.09.2024 г., 23:20 ч. UTC

Печалби

Capricorn Metals FY24 Ebitda A$168.3 Million Vs A$161.9 Million Year Prior

4.09.2024 г., 23:19 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

REA Could Need A$6.1B in Fresh Equity for Rightmove Deal -- Market Talk

4.09.2024 г., 23:19 ч. UTC

Печалби

Capricorn Metals FY24 Revenue A$359.7 Million VS A$320.7 Million Year Prior

4.09.2024 г., 23:18 ч. UTC

Печалби

Capricorn Metals FY24 Net Profit A$87.1 Million VS A$4.4 Million Year Prior

4.09.2024 г., 23:00 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Woodside's M&A Spree Likely Not Finished Yet -- Market Talk

4.09.2024 г., 22:55 ч. UTC

Пазарно говорене

Market Too Aggressive With New Zealand Rate Cut Bets -- Market Talk

4.09.2024 г., 22:39 ч. UTC

Топ новини

U.S. Accuses Russia of Spending Millions to Influence American Voters -- Update

4.09.2024 г., 22:08 ч. UTC

Печалби

Couche-Tard 1Q Profit Falls on Weakened Consumer Spending

4.09.2024 г., 21:25 ч. UTC

Топ новини

U.S. Accuses Russia of Spending Millions to Influence American Voters -- WSJ

4.09.2024 г., 21:11 ч. UTC

Печалби

Couche-Tard: Weakness in Consumer Behavior Persists >ATD.T

4.09.2024 г., 21:10 ч. UTC

Печалби

Couche-Tard: Global Fuel Demand Remained Unfavorably Impacted by Challenging Economic Conditions >ATD.T

4.09.2024 г., 21:10 ч. UTC

Печалби

Couche-Tard: Constraints on Discretionary Spending Due to Challenging Economic Conditions for Low Income Consumers >ATD.T

4.09.2024 г., 21:10 ч. UTC

Печалби

Couche-Tard: 1Q Same-store Merchandise Revenues Decreased by 3.9% in Canada >ATD.T

4.09.2024 г., 21:10 ч. UTC

Печалби

Couche-Tard: 1Q Same-store Merchandise Revenues Decreased by 2.1% in Europe and Other Regions >ATD.T

4.09.2024 г., 21:10 ч. UTC

Печалби

Couche-Tard: 1Q Same-store Merchandise Revenues Decreased by 1.1% in the US >ATD.T

4.09.2024 г., 21:07 ч. UTC

Печалби

Couche-Tard 1Q Rev $18.28B >ATD.T

4.09.2024 г., 21:07 ч. UTC

Печалби

Couche-Tard 1Q Net $790.8M >ATD.T

4.09.2024 г., 21:07 ч. UTC

Печалби

Couche-Tard 1Q Adj EPS 83c >ATD.T

4.09.2024 г., 21:07 ч. UTC

Печалби

Couche-Tard 1Q EPS 83c >ATD.T

4.09.2024 г., 21:01 ч. UTC

Придобивния, сливания и поглъщания

Mexico's Cemex Expects $209 Million From Neoris Stake Sale

4.09.2024 г., 20:46 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Verizon Nearing Deal for Frontier Communications -- 2nd Update

4.09.2024 г., 20:26 ч. UTC

Топ новини

S&P 500, Nasdaq Extend Declines Ahead of Jobs Report -- WSJ

4.09.2024 г., 20:10 ч. UTC

Топ новини

U.S. Accuses Russia of Spending Millions to Influence U.S. Voters -- WSJ

4.09.2024 г., 19:36 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Fall Ahead of Storage Report -- Market Talk

4.09.2024 г., 19:14 ч. UTC

Пазарно говорене

Price Increases Easing in the U.S., Fed Beige Book Says -- Market Talk

4.09.2024 г., 19:03 ч. UTC

Пазарно говорене

U.S. Manufacturing Declines While Home Sales Soften -- Market Talk

4.09.2024 г., 18:51 ч. UTC

Печалби

Berkshire Stock Looks Pricey After Record Run Above $1 Trillion -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

United Therapeutics Corp Прогноза

Ценова цел

By TipRanks

5.25% нагоре

12-месечна прогноза

Среден 371.91 USD 5.25%

Висок 575 USD

Нисък 280 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за United Therapeutics Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на United Therapeutics Corp през последните 3 месеца.

Техническа оценка

By Trading Central

351.61 / 365.98Подкрепа & съпротива

Bullish events outweigh bearish events.

There are no events.

Настроение

By Acuity

119 / 365 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно United Therapeutics Corp

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The Company market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution, which includes the Tyvaso Inhalation System; Orenitram (treprostinil) Extended-Release Tablets; and Adcirca (tadalafil) Tablets. In the United States, the Company also markets and sells an oncology product, Unituxin (dinutuximab) Injection, which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion.